Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients

Launched by UNIVERSITY OF FLORENCE · May 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and tolerability of a medication called atogepant for people who suffer from migraines, including those with and without aura (a warning sign before the headache) and chronic migraines. The goal is to see how well this treatment can help reduce the number of migraine days for patients who experience at least three migraines each month.

To participate in this study, individuals must have a diagnosed type of migraine according to specific guidelines and should have kept a headache diary for at least a few months before joining. It's important to note that people who are pregnant, breastfeeding, or have certain medical conditions that could affect the study results will not be eligible. Those who join can expect to follow study procedures closely and provide information about their migraine experiences to help researchers understand how well atogepant works for preventing migraines.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);
• • At least 3 monthly migraine days;
• • Good compliance to study procedures;
• • Availability of headache diary at least of the preceding months before enrollment.
• Exclusion Criteria:
• • Subjects with contraindications for use of gepants;
• • Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
• • medical comorbidities that could interfere with study results;
• • Pregnancy and breastfeeding.